Company Profile

Fubio (Suzhou) Biomedical Technology Co., Ltd., established in 2017, is a platform based company dedicated to the research and clinical translation of gene delivery vectors. We are committed to providing customers with one-stop virus products and services from basic research to clinical translation. The company has the most comprehensive and diverse virus vector library in China, with product pipelines covering lentivirus, adenovirus, adeno-associated virus (AAV), oncolytic virus, and other virus vectors; As of 2023, we have established partnerships with over 500 institutions, serving multiple fields such as life sciences, in vitro diagnostics (IVD), vaccine development, and cellular gene therapy (CGT), assisting in project research for scientific and industrial clients, and accelerating the transformation of clinical products.

The founding team is led by researchers from Fudan University and Yale University, with rich industry experience and excellent technical background. The company has gathered a team of "virus modification technology experts" who have mastered the modification technology and production capacity of more than 30 virus vectors including LVs, Adv, AAV, HPV, HIV, rabies virus, Newcastle disease virus, etc. In addition, we are equipped with independent project management, QC, and QA teams to strictly control product quality inspection. Through more than ten quality control processes, we ensure product quality. 

We always adhere to the service spirit of "quality, innovation, collaboration, and win-win", assisting in the discovery of gene therapy drugs, pharmaceutical research, accelerating the transformation of clinical products, and contributing to the cause of human health.

Main business

Fubio Biotechnology provides a full process of virus vector products and services from early research and development to preclinical development

corporate culture